今日（7月29日），A股午后拉升走高，沪指重返3600点上方，创业板指涨近2%站上2400点续创年内新 高；港股走势疲弱，但尾盘跌幅有所收窄。 具体来看，沪指早盘窄幅震荡，午后拉升收复3600点，深证成指、创业板指均大幅走高。截至收盘，沪 指涨0.33%报3609.71点，深证成指涨0.64%报11289.41点，创业板指涨1.86%报2406.59点，科创50指数涨 1.45%，沪深北三市合计成交18296亿元，较此前一日增加约630亿元。 市场走势现明显分化，保险、银行板块下挫；半导体板块拉升，东芯股份20%涨停，复旦微电涨近 10%；钢铁板块再度活跃，西宁特钢（600117）、八一钢铁（600581）涨停；创新药概念再度爆发，三 元基因涨超20%，睿智医药（300149）、辰欣药业（603367）等涨停，药明康德（603259）涨近8%； PCB概念延续强势，方邦股份连续两日涨停；CPO概念崛起，天孚通信（300394）涨近14%，中际旭创 （300308）股价突破200元续创历史新高。值得注意的是，10倍大牛股上纬新材盘中突破90元大关，再 创新高。此外，受传闻提振恒生电子（600570）强势涨停，但 ...

Market Overview - A-shares experienced a significant afternoon rally, with the Shanghai Composite Index surpassing 3600 points and the ChiNext Index rising nearly 2% to over 2400 points, marking a new high for the year [1] - The total trading volume in the Shanghai and Shenzhen markets reached 182.96 billion yuan, an increase of approximately 63 billion yuan compared to the previous day [1] Sector Performance - The insurance and banking sectors saw declines, while the semiconductor sector surged, with Dongxin Co. hitting a 20% limit up and Fudan Microelectronics rising nearly 10% [1] - The steel sector also showed strong performance, with Xining Special Steel and Bayi Steel reaching their daily limit up [1] - The innovative drug concept experienced a resurgence, with Sanmiao Gene rising over 20% and several other pharmaceutical stocks hitting their daily limit up [1][4] Notable Stocks - Wu Wei New Materials saw its stock price exceed 90 yuan, marking a new high and a cumulative increase of over 10 times since July [13] - WuXi AppTec reported a 96.20% year-on-year increase in total profit and a 101.92% increase in net profit attributable to shareholders for the reporting period [5] - WuXi AppTec's revenue from ongoing business reached 20.41 billion yuan, with significant contributions from U.S. and European clients [5] Future Outlook - WuXi AppTec expects its ongoing business revenue growth to return to double digits, with an upward adjustment of its overall revenue forecast for the year [6] - The innovative drug industry in China is transitioning to a leading position, with significant opportunities anticipated in 2025, including major international conferences that may showcase promising domestic drug data [7] - The semiconductor sector is expected to benefit from U.S. government measures aimed at strengthening domestic companies and limiting competition from China [11]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-052 无锡药明康德新药开发股份有限公司 关于调整回购股份价格上限的公告 董事長 李革博士 香港，2025年7月29日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 本公司董事会及全体董事保证本公告内容 ...

截至2025年7月28日，公司已根据2025年首次股份回购方案透过集中竞价交易方式回购合共6,514,425股 A股，占公司已发行股本总额的0.23%。2025年首次股份回购的最高价为每股A股人民币90.70元。2025 年首次股份回购的最低价为每股A股人民币65.53元。2025年首次股份回购的平均价为每股A股人民币 76.34元。所动用资金总额为人民币497,297,934.64元(不含交易费)。 格隆汇7月29日丨药明康德(02359.HK)公布，鉴于近期公司A股价格持续上涨，基于对公司未来发展的 信心和对公司价值的认可，为保障2025年首次股份回购方案的顺利实施，公司于2025年7月29日举行的 第三届董事会第二十三次会议上审议通过了《关于调整回购股份价格上限的议案》，据此，根据2025年 首次股份回购方案进行股份回购的价格上限调整为人民币114.15元╱股(含)，即不高于董事会批准《关 于调整回购股份价格上限的议案》前30个交易日公司股份交易均价的150%。除上述该调整外，有关 2025年首次股份回购方案的其他事宜维持不变。具体的A股回购数量及占公司已发行股本总额的比例以 2025年首次股份回购完成 ...

Core Viewpoint - The report from Cinda Securities highlights that WuXi AppTec's TEDIS business is driving significant growth, leading the company to raise its full-year performance guidance [1] Financial Performance - In H1 2025, the company is expected to achieve a net profit attributable to shareholders of approximately 8.56 billion yuan, representing a year-on-year increase of 101.9% [1] - In Q2 2025, the adjusted net profit attributable to shareholders is projected to be 3.64 billion yuan, reflecting a year-on-year growth of 47.9% [1] Business Growth Drivers - The strong growth in the company's chemical business is primarily driven by the high demand in the TEDIS segment [1] - The demand for peptides and oligonucleotides remains robust, with a rich order backlog [1] - The company plans to increase its peptide solid-phase synthesis capacity to over 100,000 liters by the end of 2025, indicating a positive outlook for the TEDIS business in the next 1-2 years [1] Global Market Position - Approximately 85% of the company's revenue comes from overseas clients, establishing it as a fully globalized and competitive leader in the CRDMO sector [1] - Despite geopolitical concerns, the business growth from U.S. clients remains strong in H1 2025, alleviating market worries and reinforcing the company's stable position in the global supply chain [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 茲提述(i)無錫藥明康德新藥開發股份有限公司（「本公司」）於2025年3月17日及 2025年5月14日刊發的公告（「該等公告」）；(ii)本公司於2025年3月26日刊發的通 函（「通函」）；(iii)於2025年3月26日刊發的2024年股東週年大會（「2024年股東週 年大會」）通告；及(iv)於2025年4月29日刊發的2024年股東週年大會投票結果公 告，內容有關（其中包括）2025年以集中競價交易方式回購本公司A股股份方案 （「2025年首次股份回購方案」）以及實施2024年度利潤分配及2025年特別股息分 派後調整A股回購價格上限。除非文義另有所指，否則本公告已界定的詞語在 通函及該等公告中具有相同涵義。 I. 有關2025年首次股份回購方案的資料 於2025年4月29日 ...

Investment Rating - The investment rating for WuXi AppTec is maintained as "Buy" [2][10]. Core Views - The TIDES business segment has shown remarkable performance, leading to an upward revision of the full-year revenue guidance [10]. - For the first half of 2025, the company reported a revenue of 20.799 billion RMB, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion RMB, a year-on-year increase of 101.92% [4]. - The company expects revenue growth for its continuing operations to return to double digits, with the growth rate revised from 10-15% to 13-17% [8]. Financial Performance - In H1 2025, the gross margin improved significantly to 44.45%, an increase of 5.08 percentage points year-on-year, while the net profit margin rose to 41.64%, up 16.81 percentage points year-on-year [5]. - The revenue from the chemical business reached 16.3 billion RMB, a growth of 33.5%, while the TIDES business revenue surged to 5.03 billion RMB, a staggering increase of 141.6% [6]. - The company’s total orders on hand reached 56.69 billion RMB, reflecting a year-on-year growth of 37.2% [8]. Revenue and Profit Forecast - The revenue forecast for 2025-2027 has been adjusted to 43.299 billion RMB, 49.656 billion RMB, and 56.472 billion RMB respectively, with net profit forecasts revised to 14.406 billion RMB, 13.249 billion RMB, and 15.249 billion RMB [10][12]. - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 5.02 RMB, 4.61 RMB, and 5.31 RMB respectively [10].

Market Overview - The Shanghai Composite Index rose by 0.33% on July 29, with 16 out of 28 sectors experiencing gains, led by the communication and steel industries, which increased by 3.29% and 2.59% respectively [1] - The pharmaceutical and biological industry ranked third in terms of daily gains, rising by 2.06% [1] - Conversely, the agriculture, forestry, animal husbandry, and fishery sectors, along with the banking sector, saw declines of 1.36% and 1.19% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets reached 35.637 billion yuan, with only four sectors experiencing net inflows [1] - The pharmaceutical and biological sector led the net inflow with 2.996 billion yuan, followed by the steel sector with a net inflow of 419 million yuan [1] - The non-ferrous metals sector had the highest net outflow, totaling 4.434 billion yuan, followed by the machinery equipment sector with a net outflow of 3.792 billion yuan [1] Pharmaceutical and Biological Sector Performance - The pharmaceutical and biological sector saw a net inflow of 2.996 billion yuan, with 341 out of 474 stocks in the sector rising, including 11 stocks hitting the daily limit [2] - The top three stocks with the highest net inflow were: - Zhongsheng Pharmaceutical with a net inflow of 303 million yuan and a daily increase of 9.98% - Zhifei Biological with a net inflow of 256 million yuan and a daily increase of 6.50% - Jiuzhou Pharmaceutical with a net inflow of 250 million yuan and a daily increase of 10.01% [2] - Seven stocks in the sector experienced net outflows exceeding 100 million yuan, with the largest outflows from: - Hengrui Medicine at 352 million yuan - Saili Medical at 187 million yuan - WuXi AppTec at 173 million yuan [2][4] Capital Inflow and Outflow Rankings - The top stocks by capital inflow in the pharmaceutical sector included: - Zhongsheng Pharmaceutical: +9.98%, turnover rate 15.34%, inflow 302.59 million yuan - Zhifei Biological: +6.50%, turnover rate 9.19%, inflow 255.84 million yuan - Jiuzhou Pharmaceutical: +10.01%, turnover rate 12.54%, inflow 249.88 million yuan [2] - The top stocks by capital outflow included: - Hengrui Medicine: +2.84%, turnover rate 2.64%, outflow -352.45 million yuan - Saili Medical: -4.62%, turnover rate 28.21%, outflow -186.81 million yuan - WuXi AppTec: +7.72%, turnover rate 3.78%, outflow -173.05 million yuan [4]

港股今日低开低走，三大指数盘中均一度跌超1%，尾盘跌幅则有所收窄。截止收盘，恒生指数跌0.15% 或37.68点，报25524.45点，全日成交额为2670.1亿港元；恒生国企指数跌0.34%，报9145.92点；恒生科 技指数跌0.35%，报5644.38点。 申万宏源认为，近期国内中长期改革政策加速兑现，供给侧政策（以反内卷为代表）和需求侧政策（以 生育支持政策为代表）相互配合，将有效改善宏观经济和企业盈利预期，显著提振中国资本市场的长期 信心。继续看好港股是潜在牛市中领涨市场，"牛市氛围"强化后，投资者在港股进行行业轮动会更加积 极。 蓝筹股表现 药明康德（603259）(02359)领涨蓝筹。截至收盘，涨11.25%，报111.7港元，成交额30.23亿港元，贡献 恒指6.33点。药明康德发布2025年上半年业绩，公司实现收入207.99亿元(人民币，下同)，同比增加 20.6%；母公司持有者的应占净溢利82.87亿元，同比增加95.5%。报告期内，公司持续经营收入204.1亿 元，其中来自美国客户收入140.3亿元，同比增长38.4%。此外，公司还宣布上调全年业绩指引。 其他蓝筹股方面，石药集团(0 ...

Core Viewpoint - The Hong Kong stock market experienced a decline, with the Hang Seng Index closing down 0.15% at 25,524.45 points, while the overall market sentiment remains optimistic due to accelerating domestic reform policies that are expected to improve macroeconomic conditions and corporate earnings expectations [1] Group 1: Blue Chip Performance - WuXi AppTec (02359) led the blue-chip stocks, rising 11.25% to HKD 111.7, contributing 6.33 points to the Hang Seng Index, with a reported revenue of RMB 20.799 billion for the first half of 2025, a year-on-year increase of 20.6% [2][4] - Other blue-chip stocks included CSPC Pharmaceutical Group (01093) up 8.46% and Zhongsheng Group (00881) up 6.23%, while Xiaomi (01810) and Hong Kong Exchanges and Clearing (00388) saw declines of 2.64% and 1.91%, respectively [2] Group 2: Sector Highlights - The biopharmaceutical sector saw a resurgence, with WuXi AppTec's strong interim results and upgraded annual guidance driving significant gains in the CRO sector [3][4] - The photovoltaic sector also showed recovery, with GCL-Poly Energy (03800) rising 7.69%, supported by government policies aimed at improving industry standards and eliminating excess capacity [6] Group 3: Childcare Policy Impact - The newly announced national childcare subsidy policy, effective from January 1, 2025, will provide annual subsidies of RMB 3,600 for families with children under three years old, which is expected to boost consumer spending in the maternal and infant sectors [5][6] Group 4: Notable Stock Movements - Changfei Optical Fiber (06869) saw a significant increase of 12.55%, attributed to advancements in various technology sectors [7] - Shanghai Fudan (01385) rose 9.87% following a technology service contract with Fudan University to develop advanced FPGA technology [8] - Goodbaby International (01086) issued a profit warning, expecting a decline in net profit by 40% to 50% despite slight revenue growth [11]